A need driven innovation
During over 500 hours of clinical immersion and interviews with nurses and hospital staff, our founding team discovered a critical issue: a significant amount of IV medication is trapped within IV lines, leading to patient underdosing, pharma waste, and increased risk of antimicrobial resistance.
This need for efficient and correct flushing, often overlooked or neglected, prompted our team to develop Droplet IV, a simple add-on device that automatically flushes IV lines. Our solution aims to improve patient care by ensuring proper medication dosing and reducing the workload on overburdened nurses.
Developed in collaboration with nurses from Denmark and around the world, Droplet IV aligns with global needs, routines, guidelines, and workflows, striving to enhance healthcare sustainability and combat medicine waste.
Meet the Team
Entrepreneur
15+ years in life science. MedTech entrepreneur (exited company in 2019) , advisor and board professional
LinkedIn
henriette@dropletiv.com
Henriette Schultz Kirkegaard
CEO
MBA, Engineer
20 years in RA/QA. Brought class 3 device from idea to market
mads@dropletiv.com
Mads Marker
Director RA/QA
Niklas Rädel
Head of Product Innovation, Co-Founder
Nynne Glahn
R&D Associate
LifeScience Engineer
Daniel Andreas Hager
R&D Associate
Emilie Nielsen
QA Specialist
Tore Allerup
Head of Clinical Affairs, Co-Founder
MedTech Engineer
LinkedIn
matthias@dropletiv.com
Matthias Heschel
CTO
Meet the Team
Niklas Rädel
Head of Product Innovation, Co-Founder
Mads Marker
Director RA/QA
Tore Allerup
Head of Clinical Affairs, Co-Founder
Nynne Glahn
R&D Associate
Matthias Hescel
CTO
Henriette Kirkegaard
CEO
Emilie Nielsen
QA Specialist
Daniel Andreas Hager
R&D Associate
Board Members
Malene Schrøder
Chairperson
Henriette Kirkegaard
Board Member
Tore Allerup
Board Member
Board Members
Henriette Kirkegaard
Board Member
Malene Schrøder
Chairperson
Entrepreneur
15+ years in life science. MedTech entrepreneur (exited company in 2019) , advisor and board professional
henriette@dropletiv.com
Tore Allerup
Board Member, Co-Founder
Sustainable Development Goals
Of the 17 SDGs, we directly impact 4, with indirect impacts on other goals too
We aim to ensure that all patients receive their full dosage of medicines, and at the same time reduce the risks of sepsis and other chemical irritations of the vein, which can occur during the manual flushing process of today.
Additionally, if antibiotics lose effectiveness, infectious diseases and routine treatments will become much riskier. Combatting AMR is a critical global health goal, and we aim to strengthen countries' capacities to slow its spread, aligning with target 3.d. More specifically, we hope to move the needle in the right direction on indicator 3.d.2. to reduce the percentage of bloodstream infections related to antimicrobial resistant organisms.
Targets and indicators directly impacted by Droplet IV
Target 3.d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.
Indicator 3.d.2: Percentage of bloodstream infections due to selected antimicrobial-resistant organisms
By automating the manual tasks related to IV infusion we can help nurses to do more elsewhere. Therefore we are specifically supporting technology development (target 9.b.) as well as helping to ensure adoptation of new technologies to increase resource-use efficiency of our nurses (target 9.4.).
Targets and indicators directly impacted by Droplet IV
Target 9.b: Support domestic technology development, research and innovation in developing countries, including by ensuring a conducive policy environment for, inter alia, industrial diversification and value addition to commodities.
Indicator 9.b.1: Proportion of medium and high-tech industry value added in total value added).
Target: 9.4: By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes, with all countries taking action in accordance with their respective capabilities.
Indicator 9.4.1: CO2 emission per unit of value added.
If AMR continues grow as expected and nothing is done, more and more people will be pushed into poverty which will make it increasingly difficult to progressively achieve and sustain income growth of the bottom 40% of the population, as stated by Target 10.1.
Targets and indicators directly impacted by Droplet IV
Target 10.1: By 2030, progressively achieve and sustain income growth of the bottom 40 per cent of the population at a rate higher than the national average.
Indicator 10.1.1: Growth rates of household expenditure or income per capita among the bottom 40 per cent of the population and the total population
At Droplet IV we help reduce unnecessary medicinal waste from non-flushed IV lines. It is clear that AMR is growing both due to the improper usage in humans (who underdose or are presrecribed antibiotics when unnecessary) as well as when we throw medicinal waste into nature allowing for bacteria to become resistant. See below for target information.
Targets and indicators directly impacted by Droplet IV
Target 12.4: By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment.
Indicator 12.4.2: (a) Hazardous waste generated per capita; and (b) proportion of hazardous waste treated, by type of treatment.
